(R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1H-imidazo[1,2-α]imidazol-2-one | 321656-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1H-imidazo[1,2-α]imidazol-2-one
• 英文别名: 3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1H-imidazo[1,2-a]imidazol-2-one；(R)-3-(4-bromo-benzyl)-1-(3,5-dichloro-phenyl)-5-iodo-3-methyl-1H-imidazo[1,2-a]imidazol-2-one；(R)-3-(4-bromo-benzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-imidazo[1,2-a]imidazol-2-one；(R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-hydroimidazo[1,2-a]imidazole-2-one；(5R)-5-[(4-bromophenyl)methyl]-7-(3,5-dichlorophenyl)-3-iodo-5-methylimidazo[1,2-a]imidazol-6-one
• CAS: 321656-73-9
• 化学式: C₁₉H₁₃BrCl₂IN₃O
• 分子量: 577.046
• InChiKey: IVETWPTYQWRCOV-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1H-imidazo[1,2-α]imidazol-2-one 在 氢溴酸 、 三乙胺 、 环戊基溴化镁 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 4.92h， 生成 (R)-methanesulfonic acid 3-[5-(4-bromobenzyl)-7-(3,5-dichlorophenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-α]imidazolyl-3-sulfonyl]propyl ester
  参考文献：
  名称：

  Second-Generation Lymphocyte Function-Associated Antigen-1 Inhibitors:  1H-Imidazo[1,2-α]imidazol-2-one Derivatives

  摘要：

  A novel class of lymphocyte function-associated antigen-1 (LFA-1) inhibitors is described. Discovered during the process to improve the physicochemical and metabolic properties of BIRT377 (1, Figure 1), a previously reported hydantoin-based LFA-1 inhibitor, these compounds are characterized by an imidazole-based 5,5-bicyclic scaffold, the 1,3,3-trisubstituted 1H-imidazo [1,2-alpha]imidazol-2-one (i.e. structure 3). The structure-activity relationship (SAR) shows that electron-withdrawing groups at C-5 on the imidazole ring benefit potency and that oxygen-containing functional groups attached to a C-5-sulfonyl or sulfonamide group further improve potency. This latter gain in potency is attributed to the interaction(s) of the functionalized sulfonyl/sulfonamide groups with the protein, likely polar-polar in nature, as suggested by SAR data. X-ray studies revealed that these bicyclic inhibitors bind to the I-domain of LFA-1 in a pattern similar to that of compound 1.

  DOI：

  10.1021/jm049657b
• 作为产物：
  描述：

  (2R)-2-[(2-aminoacetyl)amino]-3-(4-bromophenyl)-N-(3,5-dichlorophenyl)-2-methylpropanamide 在 三甲基氯硅烷 、 Celite 、 N,N-二异丙基乙胺 、 sodium iodide 、 copper(l) chloride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 0.83h， 生成 (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1H-imidazo[1,2-α]imidazol-2-one
  参考文献：
  名称：

  A practical synthesis of LFA-1 inhibitors utilizing CuCl-promoted intramolecular cyclization of thiohydantoins

  摘要：

  An efficient and chromatography-free approach for synthesis of a new class of LFA- I inhibitor was developed. A copper(I) chloride-promoted intramolecular cyclization of thiohydantoins 7a-b serves as a key step to highly functionalized bicyclic guanidines 5a-b, that were subsequently converted to H-imidazol[l,2-a]imidazol-2-one LFA-1 inhibitors. This process has been successfully implemented in the pilot plant to produce multikilogram quantities of LFA-1 inhibitors such as la-b. (C) 2004 Elsevier Ltd. All ri.-hts reserved

  DOI：

  10.1016/j.tetlet.2004.11.065

文献信息

• [EN] DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE [6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2 D'AMIDE D'ACIDE CARBOXYLIQUE EN TANT QU'AGENTS ANTI-INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004041273A1

  公开（公告）日：2004-05-21

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-α]咪唑-3-磺酰基]-吡咯烷-2-羧酸酰胺的衍生物表现出良好的抑制作用，可用于治疗炎症性疾病。
• DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a] IMIDAZOLE-3-SULFONIC ACID
  申请人：Barry Patrick John

  公开号：US20060264472A1

  公开（公告）日：2006-11-23

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-磺酸的衍生物对CAM和白细胞整合素的相互作用具有良好的抑制作用，因此在炎症性疾病的治疗中具有用处。
• Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides
  申请人：Wang Xiao-Jun

  公开号：US20060025447A1

  公开（公告）日：2006-02-02

  Disclosed is a multi-step process for preparing a compound of Formula I: wherein R 1 to R 3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.

  公开了一种制备化合物I的多步过程：其中R1至R3如本文所定义。化合物I的公式抑制人体细胞间粘附分子与白细胞整合素的结合。因此，这些化合物在治疗炎症和免疫细胞介导的疾病中是有用的。
• Synthesis of potent lymphocyte function-associated antigen-1 inhibitors labeled with carbon-14 and deuterium, part 1
  作者：Bachir Latli、Denis Byrne、Larry Nummy、Dhileepkumar Krishnamurthy、Chris H. Senanayake

  DOI：10.1002/jlcr.1920

  日期：2011.10

  The lymphocyte function-associated antigen-1 (LFA-1) is an essential component in normal immune system function and is a target for drug discovery for its broad therapeutic potential in treating inflammatory diseases. Here, we report the synthesis of three potent antagonists of LFA-1 labeled with carbon-14 and deuterium to support drug metabolism and pharmacokinetics studies. Carbon-14 labeled (R)-1-acetyl-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl-imidazolidine-2,4-dione (1) was prepared in 27% radiochemical yield in two steps and with a specific activity of 2.1 GBq/mmol by using [14C]-phosgene. Carbon-14 labeled 5-bromopyrimidine was used to prepare (R)-5-(1-piperazinylsulfonyl)-1-(3,5-dichlorophenyl)-3-[4-(5-pyrimidinyl)benzyl]-3-methyl-1-H-imidazo[1,2a]imidazol-2-one (2) and (R)-1-[7-(3,5-dichlorophenyl)-5-methyl-6-oxo-5-(4-pyrimidin-5-yl-benzyl)-6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]piperidin-4-carboxylic acid amide (3) via a Suzuki reaction with the corresponding boronic acid esters in 42% and 67% radiochemical yield and specific activities of 1.85 GBq/mmol and 1.95 GBq/mmol, respectively. Deuterium labeled piperazine was reacted with the sulfonyl chloride derivative (7), followed by a Suzuki coupling to the pyrimidine boronic ester to give deuterium labeled (2) in 47% yield. Deuterium labeled isonipecotamide was reacted in a similar way with the sulfonyl chloride derivative (14) to furnish deuterium labeled (3) in one step and in 94% yield. Copyright © 2011 John Wiley & Sons, Ltd.

  淋巴细胞功能相关抗原-1（LFA-1）是正常免疫系统功能的重要组成部分，因其在治疗炎症性疾病方面具有广泛的治疗潜力而成为药物研发的目标。在此，我们报告了三种用碳-14 和氘标记的 LFA-1 强效拮抗剂的合成，以支持药物代谢和药代动力学研究。通过使用[14C]-光气，我们分两步制备了碳-14标记的(R)-1-乙酰基-5-(4-溴苄基)-3-(3,5-二氯苯基)-5-甲基咪唑烷-2,4-二酮（1），放射化学收率为27%，比活度为2.1 GBq/mmol。碳-14 标记的 5-溴嘧啶用于制备 (R)-5-(1-哌嗪基磺酰基)-1-(3,5-二氯苯基)-3-[4-(5-嘧啶基)苄基]-3-甲基-1-H-咪唑并[1、2a]imidazol-2-one (2) and (R)-1-[7-(3,5-dichlorophenyl)-5-methyl-6-oxo-5-(4-pyrimidin-5-yl-benzyl)-6,1-[7-(3,5-二氯苯基)-5-甲基-6-氧代-5-(4-嘧啶-5-基苄基)-6, 7-二氢-5H-咪唑并[1,2-a]咪唑-3-磺酰基]哌啶-4-羧酸酰胺（3）通过与相应的硼酸酯发生铃木反应，放射化学收率分别为 42% 和 67%，比活度分别为 1.85 GBq/mmol 和 1.95 GBq/mmol。氘标记的哌嗪与磺酰氯衍生物 (7) 反应，然后与嘧啶硼酸酯进行铃木偶联，得到氘标记的 (2)，收率为 47%。氘标记的异哌酰胺与磺酰氯衍生物 (14) 以类似的方式进行反应，一步即可得到氘标记的 (3)，收率为 94%。Copyright © 2011 John Wiley & Sons, Ltd. All Rights Reserved.
• Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
  申请人：Kelly Alfred Terence

  公开号：US20050054704A1

  公开（公告）日：2005-03-10

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-磺酰基-吡咯烷-2-羧酸酰胺的衍生物表现出良好的抑制作用，可以用于治疗炎症性疾病，因其可以抑制细胞粘附分子和白细胞整合素之间的相互作用。